Mechanisms of Resistance to Immunotoxins Containing Pseudomonas Exotoxin A in Cancer Therapy

Synergistic antitumor effects of 9.2.27-PE38KDEL and ABT-737 in primary and metastatic brain tumors

(2019) Xin Yu et al.   PLoS One

Depletion of regulatory T cells in tumors with an anti-CD25 immunotoxin induces CD8 T cell-mediated systemic antitumor immunity

(2019) Masanori Onda et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

A phase I study of mesothelin-targeted immunotoxin LMB-100 in combination with nab-paclitaxel for patients with previously treated advanced pancreatic cancer.

(2019) Christine Campo Alewine et al.   JOURNAL OF CLINICAL ONCOLOGY

Moxetumomab pasudotox for the treatment of relapsed and/or refractory hairy cell leukemia

(2019) Iman Abou Dalle et al.   Expert Review of Hematology

5-Azacytidine prevents relapse and produces long-term complete remissions in leukemia xenografts treated with Moxetumomab pasudotox

(2018) Fabian Müller et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Diphthamide affects selenoprotein expression: Diphthamide deficiency reduces selenocysteine incorporation, decreases selenite sensitivity and pre-disposes to oxidative stress

(2018) Klaus Mayer et al.   Redox Biology

Protein Synthesis Inhibition Activity of Mesothelin Targeting Immunotoxin LMB-100 Decreases Concentrations of Oncogenic Signaling Molecules and Secreted Growth Factors

(2018) Salma El-Behaedi et al.   Toxins

Essential role for Bim in mediating the apoptotic and antitumor activities of immunotoxins

(2017) A Antignani et al.   ONCOGENE

Panbinostat decreases cFLIP and enhances killing of cancer cells by immunotoxin LMB-100 by stimulating the extrinsic apoptotic pathway

(2017) Xiu-Fen Liu et al.   Oncotarget

Protein Kinase Inhibitor H89 Enhances the Activity of Pseudomonas Exotoxin A-Based Immunotoxins

(2016) X. Liu et al.   MOLECULAR CANCER THERAPEUTICS

Reduced Shedding of Surface Mesothelin Improves Efficacy of Mesothelin-Targeting Recombinant Immunotoxins

(2016) Prince Awuah et al.   MOLECULAR CANCER THERAPEUTICS

Chemical Screens Identify Drugs that Enhance or Mitigate Cellular Responses to Antibody-Toxin Fusion Proteins

(2016) Antonella Antignani et al.   PLoS One

Actinomycin D enhances killing of cancer cells by immunotoxin RG7787 through activation of the extrinsic pathway of apoptosis

(2016) Xiu Fen Liu et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Construction of an immunotoxin, HN3-mPE24, targeting glypican-3 for liver cancer therapy

(2016) Chunguang Wang et al.   Oncotarget

Immunotoxin Therapies for the Treatment of Epidermal Growth Factor Receptor-Dependent Cancers

(2016) Nathan Simon et al.   Toxins

Multidrug Resistance Proteins (MRPs) and Cancer Therapy

(2015) Yun-Kai Zhang et al.   AAPS Journal

Anticancer Effects of Mesothelin-Targeted Immunotoxin Therapy Are Regulated by Tyrosine Kinase DDR1

(2015) Fatima Ali-Rahmani et al.   CANCER RESEARCH

The Cellular Apoptosis Susceptibility Protein (CAS) Promotes Tumor Necrosis Factor-related Apoptosis-inducing Ligand (TRAIL)-induced Apoptosis and Cell Proliferation

(2015) Prashant Monian et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Whole-genome RNAi screen highlights components of the endoplasmic reticulum/Golgi as a source of resistance to immunotoxin-mediated cytotoxicity

(2015) Matteo Pasetto et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Loss of diphthamide pre-activates NF-κB and death receptor pathways and renders MCF7 cells hypersensitive to tumor necrosis factor

(2015) Sebastian Stahl et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Methylation-Associated Partial Down-Regulation of Mesothelin Causes Resistance to Anti-Mesothelin Immunotoxins in a Pancreatic Cancer Cell Line

(2015) Kevin Hollevoet et al.   PLoS One

ABT-737 Promotes the Dislocation of ER Luminal Proteins to the Cytosol, Including Pseudomonas Exotoxin

(2014) A. Antignani et al.   MOLECULAR CANCER THERAPEUTICS

In Vitro and In Vivo Activity of the Low-Immunogenic Antimesothelin Immunotoxin RG7787 in Pancreatic Cancer

(2014) K. Hollevoet et al.   MOLECULAR CANCER THERAPEUTICS

Interleukin-4 receptor targeted immunotherapy of human bladder cancer in animal models

(2014) Bharat H Joshi et al.   Journal for ImmunoTherapy of Cancer

The Insulin Receptor Negatively Regulates the Action of Pseudomonas Toxin-Based Immunotoxins and Native Pseudomonas Toxin

(2013) X. F. Liu et al.   CANCER RESEARCH

The biosynthesis and biological function of diphthamide

(2013) Xiaoyang Su et al.   CRITICAL REVIEWS IN BIOCHEMISTRY AND MOLECULAR BIOLOGY

A Modified Form of Diphthamide Causes Immunotoxin Resistance in a Lymphoma Cell Line with a Deletion of theWDR85Gene

(2013) Hui Wei et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Combining the Antimesothelin Immunotoxin SS1P With the BH3-mimetic ABT-737 Induces Cell Death in SS1P-resistant Pancreatic Cancer Cells

(2013) Kevin Hollevoet et al.   JOURNAL OF IMMUNOTHERAPY

Methylation of the DPH1 promoter causes immunotoxin resistance in acute lymphoblastic leukemia cell line KOPN-8

(2013) Xiaobo Hu et al.   LEUKEMIA RESEARCH

Antitumor Effects of Immunotoxins Are Enhanced by Lowering HCK or Treatment with Src Kinase Inhibitors

(2013) X.-F. Liu et al.   MOLECULAR CANCER THERAPEUTICS

Combination treatments with ABT-263 and an immunotoxin produce synergistic killing of ABT-263-resistant small cell lung cancer cell lines

(2012) Abid R. Mattoo et al.   INTERNATIONAL JOURNAL OF CANCER

Phase I Trial of Anti-CD22 Recombinant Immunotoxin Moxetumomab Pasudotox (CAT-8015 or HA22) in Patients With Hairy Cell Leukemia

(2012) Robert J. Kreitman et al.   JOURNAL OF CLINICAL ONCOLOGY

Efficiency of Immunotoxin Cytotoxicity Is Modulated by the Intracellular Itinerary

(2012) Lori L. Tortorella et al.   PLoS One

Immunotoxin resistance via reversible methylation of the DPH4 promoter is a unique survival strategy

(2012) H. Wei et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

In vitro and in vivo antitumor effects of the recombinant immunotoxin IL6(T23)-PE38KDEL in multiple myeloma

(2012) DE-JUN GUO et al.   Oncology Letters

Cytotoxic Activity of Immunotoxin SS1P Is Modulated by TACE-Dependent Mesothelin Shedding

(2011) Y. Zhang et al.   CANCER RESEARCH

Killing of Resistant Cancer Cells with Low Bak by a Combination of an Antimesothelin Immunotoxin and a TRAIL Receptor 2 Agonist Antibody

(2011) Xing Du et al.   CLINICAL CANCER RESEARCH

A guide to taming a toxin - recombinant immunotoxins constructed from Pseudomonas exotoxin A for the treatment of cancer

(2011) John E. Weldon et al.   FEBS Journal

Synergistic Anticancer Effects of the 9.2.27PE Immunotoxin and ABT-737 in Melanoma

(2011) Karianne Risberg et al.   PLoS One

Pseudomonas Exotoxin A-Mediated Apoptosis Is Bak Dependent and Preceded by the Degradation of Mcl-1

(2010) X. Du et al.   MOLECULAR AND CELLULAR BIOLOGY

ABT-737 Overcomes Resistance to Immunotoxin-Mediated Apoptosis and Enhances the Delivery of Pseudomonas Exotoxin-Based Proteins to the Cell Cytosol

(2010) R. Traini et al.   MOLECULAR CANCER THERAPEUTICS

A protease-resistant immunotoxin against CD22 with greatly increased activity against CLL and diminished animal toxicity

(2008) J. E. Weldon et al.   BLOOD

PHAPI, CAS, and Hsp70 Promote Apoptosome Formation by Preventing Apaf-1 Aggregation and Enhancing Nucleotide Exchange on Apaf-1

(2008) Hyun-Eui Kim et al.   MOLECULAR CELL